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ABSTRACT
Purpose: The Maternal Malaria and Malnutrition (M3)
initiative has pooled together 13 studies with the hope
of improving understanding of malaria–nutrition
interactions during pregnancy and to foster
collaboration between nutritionists and malariologists.
Participants: Data were pooled on 14 635 singleton,
live birth pregnancies from women who had
participated in 1 of 13 pregnancy studies. The 13
studies cover 8 countries in Africa and Papua New
Guinea in the Western Pacific conducted from 1996 to
2015.
Findings to date: Data are available at the time of
antenatal enrolment of women into their respective
parent study and at delivery. The data set comprises
essential data such as malaria infection status,
anthropometric assessments of maternal nutritional
status, presence of anaemia and birth weight, as well
as additional variables such gestational age at delivery
for a subset of women. Participating studies are
described in detail with regard to setting and primary
outcome measures, and summarised data are available
from each contributing cohort.
Future plans: This pooled birth cohort is the largest
pregnancy data set to date to permit a more definite
evaluation of the impact of plausible interactions
between poor nutritional status and malaria infection in
pregnant women on fetal growth and gestational
length. Given the current comparative lack of large
pregnancy cohorts in malaria-endemic settings,
compilation of suitable pregnancy cohorts is likely to
provide adequate statistical power to assess malaria–
nutrition interactions, and could point towards settings
where such interactions are most relevant. The M3
cohort may thus help to identify pregnant women at
high risk of adverse outcomes who may benefit from
tailored intensive antenatal care including nutritional
supplements and alternative or intensified malaria
prevention regimens, and the settings in which these
interventions would be most effective.
INTRODUCTION
It is estimated that each year over 125 million
pregnant women residing in low-income and
middle-income countries (LMICs) are at risk
of infection with Plasmodium falciparum and
P. vivax.1 Malaria contributes to the high
burden of maternal morbidity and mortality
in these settings and may affect placental
development and fetal growth.2
Sequestration of P. falciparum parasites in the
placenta has been associated with fetal
growth restriction (FGR) and low birth
weight (LBW, <2500 g), thus contributing to
Strengths and limitations of this study
▪ This cohort pools data from 14 635 singleton,
live birth pregnancies in women who participated
in 1 of 13 pregnancy studies in areas with high
burdens of malaria and undernutrition.
▪ The Maternal Malaria and Malnutrition (M3)
pooled data set uses data collected at first ante-
natal attendance and at time of delivery.
▪ The data set comprises essential information on
malaria infection status, maternal anthropometric
indicators of undernutrition, presence of mater-
nal anaemia, neonatal anthropometrics and ges-
tational age at delivery, among others.
▪ The main limitation is the heterogeneity in avail-
ability of certain variables due to study design
and data collection differences between studies.
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infant mortality and possibly long-term health pro-
blems.3 4 P. vivax has also been associated with adverse
pregnancy outcomes.5 Malaria during pregnancy may
cause maternal anaemia, which itself can have deleteri-
ous effects on fetal development.2 Maternal undernutri-
tion is also common among pregnant women in these
settings,6–8 and undernourished women are more likely
to have growth-restricted fetuses and babies with
reduced birth weight.9 To date, it remains unclear
whether the susceptibility to, and the impact of, malarial
infection are affected by maternal nutritional status. A
small number of studies suggest that macronutrient
nutritional status modifies the effects of malaria in preg-
nancy, specifically the impact of P. falciparum parasit-
aemia on fetal growth and birth weight.10–12 Although
largely overlooked, this may not be surprising given that
both macronutrient and micronutrient nutritional status
affect immune function more broadly.13 14 As such,
there may be scope to design interventions that prevent
adverse pregnancy outcomes by protecting women and
their offspring from the deleterious consequences of
malaria and undernutrition. This aligns with the 2015
Global Strategy for Women’s, Children’s and
Adolescents’ Health recommendations to reduce the
risk of LBW and maternal anaemia through the preven-
tion and treatment of malaria and through adequate
nutrition during pregnancy.15 16
The Malaria in Pregnancy Consortium (MiPc), which
receives funding from the Bill & Melinda Gates
Foundation, brings together scientists whose aim is to
reduce the burden and impact of malaria in pregnancy
in LMICs.17 18 At the 2014 MiPc meeting in New
Orleans, Louisiana, USA, Consortium members identi-
fied the need to study the relationship between macro-
nutrient nutritional status and malaria in pregnancy,
given the high prevalence of undernutrition in
malaria-endemic countries. The MiPc and other malaria
researchers have conducted a number of malaria in
pregnancy studies (observational studies and
randomised controlled trials (RCTs) of malaria preven-
tion strategies) and many had collected maternal
anthropometrics and data on anaemia. Similarly, some
recent trials of nutritional supplementation during preg-
nancy collected malariometric indices. Drawing on these
data, there is a unique opportunity to study the
interaction between undernutrition and malaria,
together with other risk factors such as maternal
anaemia.
The Maternal Malaria and Malnutrition (M3) initiative
has pooled data from 13 studies with the hope of
improving the understanding of malaria–nutrition inter-
actions and to foster collaboration between nutritionists
and malariologists. Reduction of LBW and anaemia were
two of the six global nutrition targets for 2025 agreed
on at the 2012 World Health Assembly.15 As of 2014, the
Global Nutrition Report found that there was little pro-
gress towards this target.19 Risk factors for, and interven-
tions to prevent, LBW are all too commonly studied in
isolation and without cross-discipline collaboration.
Topics of interest for M3 include an evaluation of
whether macronutrient undernutrition modifies the
impact of malaria infection during pregnancy; the inves-
tigation of potential interventions that address both
malaria risk and nutritional status during pregnancy;
and the study of the role of anaemia in relation to
adverse pregnancy outcomes.
POOLED COHORT DESCRIPTION
Study populations
The M3 initiative comprises 13 studies (7 RCTs and 6
cohort studies) conducted among pregnant women in
malaria-endemic countries from 1996 to 2015.10 20–32
Studies were selected based on the availability of a pre-
determined set of essential variables for each woman,
adequate ethical clearance and willingness of
collaborators to share data. Essential variables included
the assessment of malariometric indices (light micros-
copy (LM), quantitative PCR (qPCR) and/or rapid diag-
nostic tests (RDTs)) at enrolment/first antenatal care
visit (ANC), assessment of anthropometric indicators at
enrolment (mid-upper arm circumference (MUAC)
and/or body mass index (BMI)), gravidity, type of
malaria prevention used and maternal age. Essential
delivery outcomes included birth weight and newborn
sex. With birth weight being the primary focus, we
restricted inclusion to women who delivered live single-
ton infants without congenital abnormalities, as previ-
ously recommended.33
We included 14 635 singleton, live birth pregnancies
from women who had participated in 1 of 13 pregnancy
studies (table 1) conducted in seven countries in Africa
and one in the Western Pacific (figure 1, table 1). Of
the seven RCTs, four assessed the effectiveness of differ-
ent pharmacological malaria prevention regimens,27–30
one additionally evaluated nutritional supplementa-
tion,21 one was designed solely to assess the effectiveness
of nutritional supplementation22 and one measured the
impact of insecticide-treated bed nets (ITNs) on birth
weight.25 The six prospective cohort studies were all
designed to assess risk factors and consequences of
malaria infection and/or antimalarial treatment during
pregnancy in different locations and among different
study populations.10 20 23 26 31 32
For 10 of the 13 studies, pregnant women were identi-
fied and recruited at one of their self-initiated ANC,
usually the booking visit10 20 22 27–32 but sometimes at a
subsequent visit.26 The EMEP study enrolled women
early in pregnancy, but a subset of these same women
were also enrolled in a cross-sectional study at delivery,
the intermittent preventive treatment in pregnancy
(IPTp)-MON study.23 24 The Asembo Bay ITN cohort
(Kenya) identified pregnant women through monthly
community census, and the FSP/MISAME (Burkina
Faso) study recruited through a community-based
network of home visitors.21 25 Three studies excluded
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Table 1 Characteristics of the 13 individual studies included in the M3 initiative
Countries Study name Design Period Median GA (IQR)* Malaria prevention†
Nutritional
intervention N‡ n§
Benin STOPPAM I20 Cohort 2008–2010 17 (14–20) IPT-SP None 1037 791
BF FSP/MISAME21 34 RCT 2006–2008 16 (11–21) IPT-SP(2), IPT-SP(3) MMS, FFS 1296 1020
DRC ECHO10 Cohort 2005–2006 19 (17–21) IPT-SP None 182 164
Ghana iLiNS-DYAD22 RCT 2009–2012 17 (15–20) IPT-SP LNS, MMN, IFA 1320 1068
Kenya EMEP and IPTp-MON23 24 Cohort ¶ 2011–2013 23 (16–30) IPTp-SP None 1453 473¶
Kenya ITN25 RCT 1996–1999 24 (20–30) IPT-SP started during study None 911 711
Kenya Kisumu cohort26 Cohort 1996–2001 36 (34–37) IPT-SP started during study None 3155 3388**
Kenya STOPMIP27 RCT 2012–2015 23 (20–26) IPT-SP, IPT-DHA-PQ, IST-DHA-PQ None 1546 1203
Malawi ISTp28 RCT 2011–2013 21 (19–23) IPT-SP, IST-DP None 1873 1602
Malawi LAIS29 RCT 2003–2006 20 (18–23) IPT-SP(2), IPT-SP(4) IPT-SPAZ None 1320 1190
PNG IPTp study30 RCT 2009–2013 22 (19–25) IPT-SPAZ; Single dose SP and CQ None 2793 1943
PNG Sek cohort31 Cohort 2005–2007 25 (22–28) Single dose SP and weekly CQ None 470 293
Tanzania STOPPAM II32 Cohort 2008–2010 19 (15–21) IPT-SP None 995 789
*Median (IQR): gestational age at enrolment assessed by fetal biometry, or symphysis-pubis fundal height when ultrasound unavailable.
†If RCT, describes the intervention, if cohort, describes the national policy during the study period.
‡N, enrolled in parent study.
§n, live birth pregnancies that met inclusion criteria for M3.
¶The EMEP study was a prospective cohort study with some overlapping enrolment with the cross-sectional study IPTp-MON. One hundred and eleven pregnancies were enrolled in EMEP and
IPTp-MON; information on malaria infection at delivery was obtained for the subset of women in IPTp-MON.
**Includes additional women from a substudy not included in the parent study which otherwise met inclusion criteria for the pooled data.
BF, Burkina Faso; CQ, chloroquine; DHA-PQ, dihydroartemisinin-piperaquine; DRC, Democratic Republic of the Congo; FFS, fortified food supplementation; IFA, iron and folic acid
supplementation; IPTp, intermittent preventive treatment in pregnancy; IST, intermittent screening for malaria infection; ISTp, intermittent screening for malaria infection in pregnancy; ITN,
insecticide-treated bed net; LNS, lipid-based nutrient supplementation; M3, Maternal Malnutrition and Malaria; MMS, multiple micronutrients supplementation; PNG, Papua New Guinea; RCT,
randomised controlled trial; SP, sulphadoxine-pyrimethamine; SPAZ, SP and azithromycin; STOPPAM, Strategies To Prevent Pregnancy Associated Malaria.
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HIV-infected pregnant women,22 27 28 three studies did
not assess HIV status21 30 31 and the remaining seven
studies included both HIV-infected and HIV-negative
pregnant women.10 20 23 25 26 29 32
The predominant malaria species observed in all
studies was P. falciparum. The two studies in Papua New
Guinea (PNG) also reported P. vivax infections.30 31
Some studies detected P. ovale and P. malariae infections
but prevalence was very low (<1%). Studies not differen-
tiating between species (n=4) were conducted in areas
where P. falciparum is the principal malaria species, and
P. vivax is thought to be largely absent.20–22 25 Eleven
studies reported high and perennial malaria transmis-
sion, while two studies reported medium-to-high peren-
nial malaria transmission.22 30
Measurements
Women in all studies had at least two study visits, at enrol-
ment and delivery, but the frequency and timing of
follow-up visits during pregnancy varied by study. Given
logistical and computational intensity required in pooling
longitudinal measures and substantial heterogeneity in fre-
quency and timing of measurements, only data at enrol-
ment and at delivery were pooled from every study. Tables 2
and 3 show available enrolment and delivery measurements
for each included cohort. Measurements included both
those variables deemed essential for the main analyses on
malaria, anaemia and malnutrition, and those variables
deemed optional but informative. A few measurements,
specifically malaria infection diagnostics, malnutrition
anthropometrics and anaemia diagnostics warrant further
discussion.
Malaria infection at enrolment
At enrolment, malaria infection was diagnosed by exam-
ination of peripheral blood.35 Parasitaemia was assessed
using one or more of the three following approaches:
LM examination of a Giemsa-stained blood smear, qPCR
and RDTs (table 2). In all but two studies, malaria at
enrolment was routinely diagnosed by LM. In the FSP/
MISAME study in Burkina Faso, LM was only performed
if a woman presented with symptoms consistent with
malaria, that is, fever or history of fever.21 In the
iLiNS-DYAD Ghana study, malaria was only diagnosed
using an RDT.22 RDTs detect circulating target malaria
antigens and are increasingly used in malaria-endemic
areas when microscopy is not readily available.35 36
However, persistence of circulating target antigens after
parasite clearance can lead to false-positive test results.35
Sensitivity of qPCR is much higher than LM and RDTs,
but the role of submicroscopic infections detected by
qPCR alone in causing adverse outcomes has not been
clearly determined.37 38
Malaria infection at delivery
In addition to peripheral blood diagnostics at delivery,
some studies also assessed placental malaria infection at
delivery (table 3). Placental malaria was diagnosed by
LM of a placental blood smear, qPCR and/or placental
histology.39 Three criteria are used to classify placental
malaria by histology: presence of infected erythrocytes;
haemozoin in monocytes/macrophages and haemozoin
in fibrin deposits.40 Placental histology is considered the
diagnostic reference standard for placental infection.
MUAC and BMI
Maternal macronutrient nutritional status was assessed
by measurement of women’s MUAC and/or BMI at
enrolment. MUAC, the circumference of the upper arm,
assessed at the mid-point between the elbow and the tip
of the shoulder, is frequently used as a broad indicator
of maternal protein reserves, fat stores and macronutri-
ent nutritional status.41 MUAC was measured in 10 of
the 13 studies, which included 61% of our total study
population (table 2). Weight and height (to derive BMI)
were additionally measured in nine of these studies as
well as in the three studies where MUAC was unavailable
(table 2). While neither measurement is perfect, MUAC
Figure 1 Geographical locations where the 13 parent studies were conducted: Benin, Burkina Faso, Democratic Republic of the
Congo, Ghana, Kenya, Malawi, Papua New Guinea and Tanzania.
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Table 2 Key measures at enrolment across the 13 studies included in the M3 initiative
Variable STOPPAM-Benin
FSP/
MISAME-BF ECHO-DRC iLiNS-DYAD-Ghana
EMEP and
IPTp-MON-Kenya ITN-Kenya
Kisumu-
Kenya STOPMIP-Kenya ISTp-Malawi LAIS-Malawi IPTp-PNG Sek-PNG STOPPAM-Tanzania
Essential variables
Malaria
LM X X* X X X X X X X X X X
PCR X X X X
RDT X† X‡ X§ X§ X†
Anthropometrics
MUAC X* X X X X* X¶ X X X X
Weight X X X X X X X X X X X X X
Height X X X X X X X X X X X X
Gravidity X X X X X X X X X X X X X
Anaemia**
Haemoglobin X X X X X X X X X X X X
Haematocrit X
Optional variables
Gestational age
Ultrasound X X X X X* X X X* X
Fundal height X X* X X X* X X X X X X X X
Age X X X X X X X X X X X X X
Smoking (Y/N) X X X X X X X
HIV X X X X X* X X X X X
Residence
(rural/urban)
X X X X X X X X X X X X
Bed net ownership X X X X X X X X X*
Available information indicated with X, missing data >10% indicated by *, and systematically missing data indicated with grey highlighting.
†The STOPPAM Benin and Tanzania studies primarily used the Parascreen RDT (Zephyr Biomedical Systems, Goa, India), which detects Plasmodium falciparum HRP-2 and pLDH.
‡The iLiNS-DYAD-Ghana study used the Clearview Malaria Combo RDT (British Biocell International, Dundee, UK), which detects HRP-2 and plasmodium aldolase.
§Women randomised to the ISTp arms of the STOPMIP-Kenya and ISTp-Malawi studies were tested with a First Response Malaria Ag. (pLDH/HRP2) Combo RDT (Premier Medical Corporation,
India).
¶Maternal MUAC measured at delivery.
**Nine studies measured haemoglobin using a HemoCue haemoglobinometer (Hemocue, Angelholm, Sweden),20–22 26–31 one study relied on haemoglobin measures from a local laboratory (unknown
make),23 one study used Sysmex hematological analyser (Kobe, Japan)32 and one study collected capillary blood (finger stick) specimens for determination of haematocrit or haemoglobin levels using
a standardised chart.10 In the ITN-Kenya study, haemoglobin was measured using a HemoCue haemoglobinometer (Hemocue, Angelholm, Sweden) before 1997, and from 1997 onwards capillary
blood (finger stick) specimens were collected for determination of haematocrit levels, which were divided by a factor of three and presented as haemoglobin values for consistency with the 1996 data.
BF, Burkina Faso; DRC, Democratic Republic of the Congo; HRP-2, histidine protein-2; IPTp, intermittent preventive treatment in pregnancy; ISTp, intermittent screening for malaria infection in
pregnancy; ITN, insecticide-treated bed nets; LM, light microscopy; M3, Maternal Malnutrition and Malaria; MUAC, mid-upper arm circumference; N, no; pLDH, Plasmodium lactate dehydrogenase;
PNG, Papua New Guinea; RDT, rapid diagnostic test; STOPPAM, Strategies To Prevent Pregnancy Associated Malaria; Y, yes.
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Table 3 Key measures at delivery across the 13 studies included in the M3 Initiative
Variable
STOPPAM
-Benin FSP/MISAME-BF ECHO-DRC
iLiNS-DYAD
-Ghana
EMEP and
IPTp-MON-Kenya ITN-Kenya Kisumu-Kenya
STOPMIP
-Kenya ISTp-Malawi LAIS-Malawi IPTp-PNG Sek-PNG
STOPPAM
-Tanzania
Essential variables
Malaria—peripheral
LM X* X* X X*,† X X X X X* X X X
PCR X* X X
Malaria—placental
LM X* X* X*,† X X X X X* X* X*
PCR X X X* X* X*
Histology X X X X* X*
IPTp doses received X X* X X X X* X X X
Birth weight X X X X X X X X X X X X X
Infant sex X X X X X X X X X X X X X
Optional variables
Gestational age
By ultrasound X X X X X* X X X* X
Neonatal anthropometrics
Abdomen circumference X* X X X
Chest circumference X X
Head circumference X X X X X X X X X X X
Crown heel length X X X X X X X X
Timing of anthropometrics X X X X X X X X X X X X
Available information indicated with X, missing data >10% indicated by *, and systematically missing data indicated with grey highlighting.
†For the EMEP/IPTp-MON study, only women co-enrolled in the IPTp-MON study (n=111) had malaria diagnostics at delivery.
BF, Burkina Faso; DRC, Democratic Republic of the Congo; IPTp, intermittent preventive treatment in pregnancy; ISTp, intermittent screening for malaria infection in pregnancy; ITN,
insecticide-treated bed nets; LM, light microscopy; M3, Maternal Malnutrition and Malaria; PNG, Papua New Guinea; STOPPAM, Strategies To Prevent Pregnancy Associated Malaria.
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and BMI are easy and low-cost nutritional assessments
that can be undertaken in low-resource settings, and are
clinically relevant.42
Anaemia at enrolment
Most women had haemoglobin measurements per-
formed at first ANC, and most received routine iron/
folate supplements, although information on their use
was not routinely collected. The dosage of folate supple-
mentation (0.4–5 mg) varied by study site.
FINDINGS TO DATE
Findings from each individual study emphasise how
pooling these data has the potential to generate import-
ant information on malaria–nutrition interactions in
pregnancy.
The ECHO study in the Democratic Republic of the
Congo (DRC) was the first study to report an interaction
between malaria and malnutrition on the risk of FGR.10
In this study, the risk of FGR was 2–8 times higher
among women with evidence of malnutrition. In this
study, the magnitude of the difference in effect sizes
depended on the measurement for malnutrition (BMI
vs MUAC vs short stature vs weight gain) and the meas-
urement for malaria (cross-sectional vs cumulative);
however, with all measurements of malnutrition and
malaria, the pattern and directionality of the modifica-
tion was consistent. This study, together with a small
number of follow-up studies, provided the necessary pre-
liminary data for the M3 initiative.7 12
Two participating studies provided evidence regarding
nutritional interventions during pregnancy. The FSP/
MISAME in Burkina Faso study concluded that multiple
micronutrient-fortified food supplementation increased
mean birth weight, and that this effect was most pro-
nounced among women who were anaemic or under-
nourished early in their pregnancy.34 The iLiNS-DYAD
trial in Ghana found modest overall increases in birth
weight with the provision of lipid-based nutrient supple-
ments compared with iron and folic acid supplementa-
tion, but showed that the intervention may be most
effective when given to primiparous women.22 While
nutritional assessment was not the primary aim of the
remaining studies, the IPTp RCT in PNG and the
Strategies To Prevent Pregnancy Associated Malaria
(STOPPAM) cohort study in Benin reported associations
between low maternal anthropometrics and birth
weight.20 43
Other studies largely focused on malaria prevention.
In the late 90s, the Kisumu cohort study found that
implementation of two doses of IPT-sulphadoxine-
pyrimethamine (SP) halved the prevalence of placental
malaria infection. In another study conducted concur-
rently in Kenya (Asembo Bay study) use of ITNs was
associated with a marked reduction in placental malaria
and LBW, but (as expected) with no apparent impact
on nutritional status.25 The LAIS study, conducted in
Malawi from 2003 to 2006, found that adding azithromy-
cin to two courses of monthly SP (SPAZ) was better at
reducing malaria at delivery, LBW and preterm birth
than monthly SP or two doses of SP.29 44 45 SPAZ was
also superior when compared with the standard malaria
prevention regimen used in PNG (SP plus chloro-
quine),30 where placental infection is an important risk
factor for LBW.31 The EMEP cohort study found that
use of artemisinin combination treatments during the
first trimester was not associated with increased risk of
miscarriage.23 The IPTp-MON study found that with
increasing resistance, the efficacy of IPTp-SP in clearing
existing infections or preventing new ones is compro-
mised; however, where the sextuple mutant is rare, it
remains associated with improvements in birth weight
and maternal haemoglobin.24
The STOPPAM cohort studies conducted in Benin
and Tanzania provided observational data on the effects
and potential limitations of two-dose IPTp-SP.
Specifically, the STOPPAM-Benin study found that a sub-
stantial proportion of women acquired malaria infec-
tions late in pregnancy, sometimes after the second
IPTp dose had been given.20 The STOPPAM-Tanzania
study also found that malaria infections in the first or
second trimester were associated with altered fetal
growth that might not be detectable until the third tri-
mester.32 Trial data from the FSP/MISAME study further
corroborated these observational studies; the FSP/
MISAME study found that malaria infection during the
first trimester was associated with higher risk of LBW
and that additional doses of IPTp might be more effect-
ive.21 46 These studies, along with others, have high-
lighted the importance of early and frequent malaria
prevention to improve birth outcomes, and IPT-SP is
now routinely given monthly until delivery.47 48
The intermittent screening for malaria infection
(ISTp) Malawi study assessed another malaria preven-
tion strategy by comparing IPTp-SP with ISTp at ANC
visits using RDTs and treating infected women with
dihydroartemisinin-piperaquine (DHA-PQ).28 The
STOPMIP Kenya study also assessed ISTp with DHA-PQ,
comparing it to IPTp with DHA-PQ as well as IPTp-SP.
Analyses from both studies suggest that ISTp-DHA-PQ is
not superior to the existing strategy of IPTp-SP, although
IPTp-DHA-PQ was more effective than both ISTp-DP
and IPTp-SP.27
FUTURE PLANS
We plan to assess whether maternal macronutrient nutri-
tional status, as assessed by MUAC, BMI and maternal
height, alters the risk of reduced birth weight that is
associated with malaria infection during pregnancy.
Among women who underwent a dating ultrasound scan
in early pregnancy, analyses will be performed using
preterm birth and small-for-gestational age as end points
in addition to LBW. To inform policy decisions, we
further plan to use advanced epidemiological methods
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to stochastically model the impact that plausible targeted
antimalarial and nutritional interventions during preg-
nancy could have on the number of babies born LBW in
malaria endemic areas.49–51 Additional future analyses
include, but are not limited to, the following: the impact
of anaemia on LBW; the interaction between anaemia
and malaria with regard to increasing the risk of LBW;
the mediation of the effect of malaria through anaemia
on LBW; and the usefulness and agreement of MUAC
versus BMI to predict adverse birth outcomes. Short
maternal stature, potentially indicative of stunting and
reduced adolescent catch-up growth (chronic undernu-
trition), has also been associated with increased risks of
adverse birth outcomes and will be explored using this
pooled data set.52 Finally, we will assess aforementioned
relationships and effects among pregnant women with
HIV, a patient cohort known to be at increased risk of
adverse outcomes due to malaria and malnutrition.53
STRENGTHS AND LIMITATIONS
This pooled birth cohort holds promise as the largest preg-
nancy data set to date to address questions regarding
malaria and nutrition that are of great importance to
maternal and infant health. Prior research on this topic
has been limited by insufficient statistical power to
examine the interaction between malaria and malnutri-
tion. The pooled M3 offers the opportunity to overcome
this limitation by increasing statistical power and precision,
which is particularly valuable for conducting subgroup ana-
lyses and investigating interactions. The substantial size of
the pooled data set also facilitates the application of rigor-
ous methodological approaches for systematically missing
data, such as multiple imputation by chained equations,
standardisation, latent variable methods or transformation
of measurements to create commensurate measures.54 55
Availability of individual-level data, rather than aggregate
data from each study, allows definitions of exposures and
outcomes to be harmonised. Individual-level information
on malaria and malnutrition further enables implementa-
tion of complex modelling to assess targeted antimalarial
and nutritional interventions during pregnancy. The diver-
sity of study populations included in the M3 cohort, for
example, with respect to location, ethnicity, malaria trans-
mission intensity, malaria and nutrition interventions,
health infrastructure and HIV prevalence, could provide
important data with regard to generalisability of our find-
ings. Specifically, this level of population diversity, coupled
with availability of data on multiple risk factors for LBW
and greater statistical power to assess subgroup effects, may
allow the identification of high-risk women who could
benefit most from more intensive antenatal care, nutri-
tional supplements and alternative malaria prevention regi-
mens, and of the settings in which these interventions
would be most effective.
The main limitations of the pooled data set are
related to missing data and heterogeneity of the col-
lected data. First, information that was collected by all
studies varied, leading to systematically missing data on a
number of important variables (tables 2 and 3). The
limited availability of accurately measured gestational
age hinders the ability to conduct preterm birth and
small-for-gestational age analyses for the entire data set
(table 3), but should allow for meaningful subanalyses.
Second, exclusion of miscarriages and stillbirths may
cause selection bias (left truncation) for some analyses,
given the possibility of differential rates of early preg-
nancy losses in relation to infection and nutritional
status.56 We will assess this potential bias using data on
miscarriages and stillbirths extracted from a subset of
studies.21 23 27 28 Third, potential confounders such as
concomitant helminth infection and micronutrient defi-
ciencies were not measured in participant studies.57 58
Fourth, while MUAC only modestly changes throughout
pregnancy, BMI tends to increase with gestational age:
gestational age-adjusted BMI may be one approach to
address this problem. Fifth, while we have information
on HIV status for a majority of studies, information on
use of antiretroviral therapy (ART) was not extracted,
and secular changes over time regarding use and effi-
cacy of ARTs could influence the comparability of results
across studies that enrolled HIV-infected women. Finally,
since the intention was to concentrate on areas of
moderate-to-high P. falciparum transmission, we did not
include any studies representing other malaria-affected
regions such as Central/South America and India.
COLLABORATION
The investigators welcome collaboration for future pro-
jects and invite proposals for additional analyses.
Further details can be obtained by contacting SR (sro-
ger@unimelb.edu.au) and HWU (hwunger@doctors.
org.uk).
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